HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
Elicio Therapeutics Added To Russell 2000, 3000 Indexes, Effective June 26
Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
Elicio Therapeutics Reports 100% Complete Responses In Three Metastatic Pancreatic Cancer Patients Following ELI-002 7P And Nivolumab Therapy
Jones Trading Downgrades Elicio Therapeutics to Hold
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints
Elicio Therapeutics Shares Plunge After Pancreatic Cancer Study Misses Main Goal (ELTX)
Elicio Therapeutics Pancreatic Cancer Study Disappoints
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $23
Elicio Therapeutics Reports Results From Randomized Phase 2 AMPLIFY-7P Study Evaluating ELI-002 7P In Patients With Adjuvant mKRAS-Driven Pancreatic Ductal Adenocarcinoma
B. Riley Securities Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $27
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.